Efficiency of tazobactam/piperacillin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2-pneumoperitoneum

Shock

Volumn 25, Issue 1, 2006, Pages 23-29

  Bette, Michael ^a   Nüsing, Rolf M ^a   Mutters, Reinier ^a   Zamora, Zullyt B ^b   Menendez, Silvia ^b   Schulz, Siegfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Antibiotic therapy; Cytokines; Mortality; Oxidative stress; Sepsis

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; INTERLEUKIN 1; OZONE; PENICILLANIC ACID; PIPERACILLIN; TAZOBACTAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; MALE; METABOLISM; PATHOLOGY; PERITONITIS; PNEUMOPERITONEUM; RAT; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; INTERLEUKIN-1; MALE; OZONE; PENICILLANIC ACID; PERITONITIS; PIPERACILLIN; PNEUMOPERITONEUM; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646376688     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000187983.56030.dd     Document Type: Article

References (45)

1. Hedberg M, Nord CE: Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 9:475-488, 2003.
2. Livermore DM, Mushtaq S, James D, Potz N, Walker RA, Charlett A, Warburton F, Johnson AP, Warner M, Henwood CJ: In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Int J Antimicrob Agents 22:14-27, 2003.
3. Platsouka E, Zissis NP, Portolos J, Paniara O: Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review. J Chemother 15:27-30, 2003.
4. Bressler RB, Huston DP: Piperacillin-induced anemia and leukopenia. South Med J 79:255-256, 1986.
5. Gerber L, Wing EJ: Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Clin Infect Dis 21:1047-1048, 1995.
6. Reichardt P, Handrick W, Linke A, Schille R, Kiess W: Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment - a retrospective analysis in 38 children with cystic fibrosis. Infection 27:355-356, 1999.
7. Ruiz-Irastorza G, Barreiro G, Aguirre C: Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 95:611-612, 1996.
8. Singh N, Yu VL, Mieles LA, Wagener MM: Beta-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med 94:251-256, 1993.
9. Wilson C, Greenhood G, Remington JS, Vosti KL: Neutropenia after consecutive treatment courses with nafcillin and piperacillin. Lancet 1:1150, 1979.
10. Broadberry RE, Farren TW, Bevin SV, Kohler JA, Yates S, Skidmore I, Poole J, Garratty G: Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells. Transfus Med 14:53-57, 2004.
11. Kucers A, Crowe S, Grayson M, Hoy J: The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, and Antiviral Drugs. 5th ed. Oxford: Butterworth-Heinemann, 1997.
12. Powell LL, Wilson SE: The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect (Larchmt) 1:57-63, 2000.
13. Komuro M, Maeda T, Kakuo H, Matsushita H, Shimada J: Inhibition of the renal excretion of tazobactam by piperacillin. J Antimicrob Chemother 34:555-564, 1994.
14. Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Viticchi C, Scalise G, Saba V: Cationic peptides combined with betalactams reduce mortality from peritonitis in experimental rat model. J Surg Res 108:107-111, 2002.
15. Rotimi VO, Al-Sweih NN, Anim JT, Ahmed K, Verghese TL, Khodakhast FB: Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy. J Chemother 13:510-518, 2001.
16. Larsson A, Engstrom M, Uusijarvi J, Kihlstrom L, Lind F, Mathiesen T: Hyperbaric oxygen treatment of postoperative neurosurgical infections. Neurosurgery 50:287-295, 2002; discussion 295-296.
17. Zamboni WA, Browder LK, Martinez J: Hyperbaric oxygen and wound healing. Clin Plast Surg 30:67-75, 2003.
18. Cuzzocrea S, Imperatore F, Costantino G, Luongo C, Mazzon E, Scafuro MA, Mangoni G, Caputi AP, Rossi F, Filippelli A: Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat. Shock 13:197-203, 2000.
19. Thom SR, Lauermann MW, Hart GB: Intermittent hyperbaric oxygen therapy for reduction of mortality in experimental polymicrobial sepsis. J Infect Dis 154:504-510, 1986.
20. Akin ML, Uluutku H, Erenoglu C, Ilicak EN, Elbuken E, Erdemoglu A, Celenk T: Hyperbaric oxygen ameliorates bacterial translocation in rats with mechanical intestinal obstruction. Dis Colon Rectum 45:967-972, 2002.
21. Schulz S, Rodriguez ZZ, Mutters R, Menendez S, Bette M: Repetitive pneumoperitoneum with ozonized oxygen as a preventive in lethal polymicrobial sepsis in rats. Eur Surg Res 35:26-34, 2003.
22. Babior BM, Takeuchi C, Ruedi J, Gutierrez A, Wentworth P Jr: Investigating antibody-catalyzed ozone generation by human neutrophils. Proc Natl Acad Sci USA 100:3031-3034, 2003.
23. Bochkov VN, Leitinger N: Anti-inflammatory properties of lipid oxidation products. J Mol Med 81:613-626, 2003.
24. Leitinger N: Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 14:421-430, 2003.
25. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N: Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419:77-81, 2002.
26. Reed MD, Goldfarb J, Yamashita TS, Lemon E, Blumer JL: Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 38:2817-2826, 1994.
27. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L: Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 14:829-837, 1978.
28. Young M, Plosker GL: Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. Pharmacoeconomics 19:1135-1175, 2001.
29. Holzheimer RG, Dralle H: Antibiotic therapy in intra-abdominal infections - a review on randomised clinical trials. Eur J Med Res 6:277-291, 2001.
30. Chinnaiyan AM, Huber-Lang M, Kumar-Sinha C, Barrette TR, Shankar-Sinha S, Sarma VJ, Padgaonkar VA, Ward PA: Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. Am J Pathol 159:1199-1209, 2001.
31. Gonzales J, Aguirre A, Salgado JL: Estudio toxicologico agudo y cronico del ozono administrado por via intraperitoneal en distintas espscies. In: Libro de Resumenes Primer Congresso Iberolatinoamericana de Aplicactiones del Ozono La Habana, Cuba: 15, 31 Oct.-3 Nov., 1990.
32. Gomez-Barry H, Barber E, Menendez S, Gomez M: Estudio estructural y ultrastructural de organos de ratas sometidas a la administracion intraperitoneal de ozono. Libro de Resumenes Primer Congresso Iberolatinoamericano de Aplicactiones del Ozono, La Habana, Cuba: 15, 31 Oct.-3 Nov., 1990.
33. Rokitansky O, Rokitansky A: Electron microscopic studies on capillary endothelium cells and on the peritoneum after application of ozone/oxygen in animals. Proceedings of the 8th Ozone World Congress, Zurich, Switzerland 3:M25, 15-18 Sept., 1987.
34. Kadl A, Huber J, Gruber F, Bochkov VN, Binder BR, Leitinger N: Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. Vascul Pharmacol 38:219-227, 2002.
35. Ma Z, Li J, Yang L, Mu Y, Xie W, Pitt B, Li S: Inhibition of LPS- and CpG DNA-induced TNF-alpha response by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol 286:L808-L816, 2004.
36. Zamora ZB, Borrego A, Lopez OY, Delgado R, Gonzalez R, Menendez S, Hernandez F, Schulz S: Effects of ozone oxidative preconditioning on TNF-α release and antioxidant-prooxidant intracellular balance in mice during endotoxic shock. Mediators Inflamm 2005:16-22, 2005.
37. Han J, Brown T, Beutler B: Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 171:465-475, 1990.
38. Vianna RC, Gomes RN, Bozza FA, Amancio RT, Bozza PT, David CM, Castro-Faria-Neto HC: Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 21:115-120, 2004.
39. Hildebrand F, Pape HC, Hoevel P, Krettek C, van Griensven M: The importance of systemic cytokines in the pathogenesis of polymicrobial sepsis and dehydroepiandrosterone treatment in a rodent model. Shock 20:338-346, 2003.
40. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A: Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22:460-466, 2004.
41. Kotake Y, Moore DR, Vasquez-Walden A, Tabatabaie T, Sang H: Antioxidant amplifies antibiotic protection in the cecal ligation and puncture model of microbial sepsis through interleukin-10 production. Shock 19:252-256, 2003.
42. Macdonald J, Galley HF, Webster NR: Oxidative stress and gene expression in sepsis. Br J Anaesth 90;221-232, 2003.
43. Webster NR, Nunn JF: Molecular structure of free radicals and their importance in biological reactions. Br J Anaesth 60:98-108, 1988.
44. Jacobs S, Sobki S, Morais C, Tariq M: Effect of pentaglobin and piperacillin on survival in a rat model of faecal peritonitis: importance of intervention timings. Acta Anaesthesiol Scand 44:88-95, 2000.
45. Ajamieh HH, Menendez S, Martinez-Sanchez G, Candelario-Jalil E, Re L, Giuliani A, Fernandez OS: Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusion. Liver Int 24:55-62, 2004.